Answers are grounded in this paper and cite their sources.
Objective: Ro52/TRIM21 is a cytoplasmic protein that binds intracellular antibodies and drives their proteasomal degradation. Autoantibodies targeting Ro52 frequently co-occur with myositis-specific autoantibodies, including anti-MDA5, and patients with both autoantibodies have greater disease severity and interstitial lung disease risk. We previously demonstrated that internalized anti-MDA5 autoantibodies promote interferon-stimulated gene expression in cultured myoblasts. Here, we investigated the interactions between anti-Ro52 and coexisting autoantibodies, including anti-MDA5. Methods: Primary human skeletal muscle myoblasts were electroporated with purified IgG from healthy controls or patients with anti-MDA5, anti-Mi-2, or anti-PM/Scl antibodies, combined with anti-Ro52-positive IgG from patients with myositis, Sjögren′s disease, or systemic sclerosis. Affinity-purified anti-Ro52 was also used to validate findings obtained using total IgG. Cells underwent bulk RNA sequencing 24 hours after internalization. Results: Co-internalization of anti-Ro52 with anti-MDA5 enhanced the anti-MDA5-induced type I interferon transcriptional response and expression of type II interferon-inducible genes compared with anti-MDA5 and control IgG. Increased expression of IFNB1, ISG15, MX1, and the interferon-g-inducible inflammatory chemokines CXCL9 and CXCL10 was observed across independent patient-derived antibody combinations, anti-Ro52 preparations from multiple autoimmune diseases, and affinity-purified anti-Ro52. Conversely, co-internalization of anti-Ro52 with anti-Mi-2 or anti-PM/Scl reduced expression of transcripts associated with these nuclear autoantibodies. Conclusions: These findings demonstrate that anti-Ro52 autoantibodies potentiate the activation of interferon pathways stimulated by the internalization of anti-MDA5 antibodies. We propose that in patients with anti-MDA5 autoantibodies, co-existing anti-Ro52 antibodies may exacerbate disease by inhibiting the proteasomal degradation of internalized anti-MDA5 antibodies and thereby enhancing the expression of interferon and interferon-stimulated genes.
No takes yet. Share an insight, caveat, or question.
Ebadi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: